LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global POC Diagnostics Devices and Equipment Market to Surpass USD 50 Billion in 2026

By LabMedica International staff writers
Posted on 08 Jun 2022
Print article
Image: The POC diagnostics devices and equipment market is estimated to be worth almost USD 29 billion in 2022 (Photo courtesy of Unsplash)
Image: The POC diagnostics devices and equipment market is estimated to be worth almost USD 29 billion in 2022 (Photo courtesy of Unsplash)

Point-of-care (POC) diagnostics devices and equipment are designed to aid physicians in performing medical diagnostic testing at or near the point of care, for immediate knowledge on diseases or conditions. An increase in the incidence of target diseases is driving the POC devices and equipment market globally. The rising incidence of chronic diseases, like diabetes, rheumatism, or cancer is increasing steadily worldwide due to poor lifestyle choices and increasing obesity, thus driving the growth of the POC devices and equipment market. The global POC diagnostics devices and equipment market is expected to grow at a CAGR of 17.6% from USD 24.44 billion in 2021 to USD 28.74 billion in 2022 and is projected to grow further at a CAGR of 15.8% to reach USD 51.73 billion in 2026.

These are the latest findings of Research and Markets (Dublin, Ireland), the world’s largest market research store.

POC diagnostic devices and equipment comprise mainly infectious disease testing kits, cardiometabolic monitoring kits, cholesterol testing kits, pregnancy and fertility tests kits, tumor/cancer markers, urinalysis testing kits, hematology testing kits, drugs of abuse testing kits, fecal occult testing kits, and others. Pregnancy and fertility tests kits in POC diagnostic devices are used to test for pregnancy and fertility in advance before going to the doctor.

POC diagnostic devices and equipment includes prescription-based and over-the-counter (OTC) testing devices which have a large base of end-users such as professional diagnostic centers, hospitals/critical care centers, outpatient healthcare settings, ambulatory care settings, research laboratories, and homes. OTC testing is being seen as a key growth driver of the POC diagnostics market as it improve access to testing and enables early detection of diseases. The US FDA has approved OTC test kits for cholesterol, fecal occult blood, pregnancy, and HIV/HCV. These testing kits are likely to generate more revenue than prescription tests over the forecast period due to ease of using the kits, increased home care and self-testing, and a rise in their availability and adoption rate. In 2021, North America was the largest POC diagnostic devices and equipment market followed by the Asia Pacific region.

Related Links:
Research and Markets 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more